An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed signs of therapeutic benefit in a clinical trial led by the National Institutes of Health.
Pα+ Psychedelic Bulletin #162: EQUULUS Therapeutics Emerges from Stealth; Responses to ICER’s Draft Evidence Report on Lykos’ MDMA; and more… – Psychedelic Alpha
Featured content in this Issue: EQUULUS Therapeutics Emerges from Stealth with Non-Hallucinogenic Ibogaine Analog as Lead Candidate Responses to ICER’s Draft Evidence Report on MDMA-Assisted
April 25, 2024